Portage Biotech Corp - חוב לטווח קצר של החברה PRTG
Portage Biotech Inc. (PRTG) is a biotech holding company recognized for its methods of accelerating the development of anti-tumor agents. The firm's investment strategy relies on managing biopharmaceutical assets to generate future royalties. This price chart on the GURU.Markets platform reflects a metric of 0.00. However, the company currently faces the threat of bankruptcy due to a shortage of funds to conduct medical trials.
%3A%20%D7%94%D7%9C%D7%95%D7%95%D7%90%D7%95%D7%AA%20%D7%95%D7%90%D7%A9%D7%A8%D7%90%D7%99%20%D7%9C%D7%98%D7%95%D7%95%D7%97%20%D7%A7%D7%A6%D7%A8%20%D7%A9%D7%9C%20%D7%94%D7%97%D7%91%D7%A8%D7%94&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_PRTG_-_Portage-Biotech-Inc._-_Company-Short-Term-Loans-and-Borrowings "PRTG Portage Biotech Inc.: חובות לטווח קצר של החברה בטווח 04.07.2022 - 04.09.2025 | 👁️GURU.Markets👁️")
Portage Biotech Corp - פילוחים אנליטיים ומדדי מפתח (PRTG)
To select high-quality assets, an investor must evaluate a business's ability to service its obligations over a short-term horizon. This metric aggregates all accounts payable with maturities of up to one year, which is critical for Portage Biotech Inc. (PRTG) amid frozen grants and capital shortages; therefore, the trend in total short-term debt serves as an indicator of the risk of an imminent cash crunch.